ResearcherBC Cancer AgencyNo recent work listed

Ning Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1566-3184; OpenAlex author ID A5100642732. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper

Papers 2

A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer. Co-author DOI 10.1007/s44178-023-00042-z ↗
Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces the stability of SMAD4 in Panc-1 cells. First author DOI 10.21037/atm-22-1085 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yuzhuo Z. Wang · 1 shared paper, 2023 · strength 0.31
- Paper A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer. DOI 10.1007/s44178-023-00042-z ↗
Jia Hou · 1 shared paper, 2022 · strength 0.17
- Paper Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces the stability of SMAD4 in … DOI 10.21037/atm-22-1085 ↗
Youhua Xie · 1 shared paper, 2022 · strength 0.17
- Paper Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces the stability of SMAD4 in … DOI 10.21037/atm-22-1085 ↗
Jing Liu · 1 shared paper, 2022 · strength 0.17
- Paper Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces the stability of SMAD4 in … DOI 10.21037/atm-22-1085 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.